Category - Markets

H.C. Wainwright downgraded Advaxis (NASDAQ:ADXS) to “neutral” from “buy” and removed its price target after Amgen terminated a development and collaboration agreement on ADXS-NEO, Advaxis’ personalized neoantigen...

Roth Capital Markets launched coverage of CollPlant Holdings (NASDAQ:CLGN) with a “buy” rating and 12-month price target of $7. The stock closed at $4.36 on Dec. 17. CollPlant is the world’s first and only commercial...

Roth Capital Partners raised its price target for Arch Therapeutics (OTCQB:ARTH) to $3 from $2.10 after the FDA cleared the company’s AC5 Topical Gel for use in partial and full-thickness skin wounds, such as pressure...

Canopy Growth (TSX:WEED; NYSE:CGC) entered into a multi-year extraction agreement with Valens GroWorks (CSE:VGW; OTC:MYMSF), a licensed provider of cannabis products and services focused on various extraction...

Leerink Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with an “outperform” rating and $24 price target. The stock closed at $9.64 on Dec. 12. Millendo is developing treatments for rare, debilitating...

H.C. Wainwright analyst Ed Arce assumed coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and price target of $2.50. The stock closed at $1.04 on Dec. 12. Organovo was founded in 2007 as a CRO, offering...

AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...

Maxim Group raised its price target for Quantum Genomics SA (Euronext Growth – FR0011648971 – ALQGC) to €9 from €6 after the company held a recent key opinion leader and investor day. The stock closed at €5...

Analysts at Canaccord Genuity and BTIG launched coverage of Vapotherm (NYSE:VAPO) with “buy” ratings and price targets of $25 and $26, respectively. The stock closed at $20.93 on Dec. 7. Vapotherm sells Precision Flow...

Stifel downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “hold” from “buy” and slashed its price target to $4 from $10 after the company’s ENCORE-PH trial missed its pre-specified primary endpoint. The stock closed at...